Trials / Completed
CompletedNCT00630500
Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)
A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Helse Stavanger HF · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A 24-week placebo-controlled parallel group multicentre trial to study the safety and efficacy of memantine in patients with dementia associated with Parkinson's disease and dementia with Lewy bodies. It is hypothesized that memantine will be safe and well tolerated, and more effective than placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Memantine | Tablets, 5 or 10 mg, twice daily |
| DRUG | Placebo | Tablets corresponding to 5 or 10 mg, twice daily, 6 months |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2009-02-01
- Completion
- 2009-03-01
- First posted
- 2008-03-07
- Last updated
- 2015-07-28
Locations
4 sites across 3 countries: Norway, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00630500. Inclusion in this directory is not an endorsement.